Device deals climb with a focus on cancer, cardiovascular markets

The number of medical device deals and their disclosed values appear to be rising, according to data from Cortellis Deals Intelligence (CDI).

Read more >

AMPs take aim at AMR as biopharma seeks new solutions to resistance

Antimicrobial resistance (AMR) is a topic that just won't go away, and for good reason. Despite the plethora of threats facing humankind, including thousands of diseases in need of therapies or cures, many scientists worry that the biggest risk of extinction comes from the deadly pathogens that exist in uneasy cohabitation on planet Earth.

Read more >

Preserving, boosting innovation crucial in age of Brexit, Trump

To the imponderables of the Brexit vote to leave the EU, U.K. biotech investors must now add the uncertainties generated by U.S. President Donald Trump’s pledge to bring down drug prices.

Read more >

How do biotechs use Web of Science?

The world of biotech companies changes rapidly, alongside the constantly evolving research landscape.

Read more >

Cortellis Deals Landscape Q4 2016

During the 4th quarter of 2016, Cortellis Competitive Intelligence had 889 new deals added as part of its ongoing coverage of pharmaceutical licensing activity.

Read more >